Literature DB >> 23244433

Restless legs syndrome in multiple sclerosis.

Chiara Zecca1, Mauro Manconi, Stephany Fulda, Claudio Gobbi.   

Abstract

There is a growing interest in sleep disorders in multiple sclerosis (MS) due to their high frequency and possible relationship to fatigue, a hallmark symptom in MS. Among them, insomnia and restless legs syndrome (RLS) are the most common ones. RLS is a sleep-related motor disorder characterized by a strong urge to move associated with uncomfortable sensations in the limbs. It is frequently under diagnosed in patients with MS although its course is often particularly severe. Several arguments support a symptomatic origin of RLS in MS patients. Independently of any causal relationship, the high prevalence of RLS in MS patients has clinical implications. The purpose of the present review is (i) to summarize the epidemiological data and clinical characteristics of RLS in MS patients in order to increase sensitivity to this disorder; (ii) to document the substantial body of evidence in support of a symptomatic origin of RLS in MS and from this (iii) to delineate the proposition that MS may represent a clinical model to study RLS-associated pathological changes.

Entities:  

Mesh:

Year:  2012        PMID: 23244433     DOI: 10.2174/1871527311211080017

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  2 in total

Review 1.  Movement Disorders in Multiple Sclerosis: An Update.

Authors:  Ritwik Ghosh; Dipayan Roy; Souvik Dubey; Shambaditya Das; Julián Benito-León
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2022-05-04

2.  Leg movement activity during sleep in multiple sclerosis with and without restless legs syndrome.

Authors:  Raffaele Ferri; Davide Sparasci; Anna Castelnovo; Silvia Miano; Kosuke Tanioka; Naoko Tachibana; Chiara Carelli; Gianna Carla Riccitelli; Giulio Disanto; Chiara Zecca; Claudio Gobbi; Mauro Manconi
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.